VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Monoclonal antibody combinations in ALL

VJHemOnc is committed to improving our service to you

Francesco Lanza

Francesco Lanza, MD, Ravenna Hospital, Ravenna, Italy, outlines the sequential use of novel monoclonal antibodies for the treatment of adult acute lymphoblastic leukemia (ALL) who are relapsed/refractory to chemotherapy, including blinatumomab, a CD19 targeting monoclonal antibody, as well as inotuzumab ozogamicin, an antibody-drug conjugate. Dr Lanza also discusses the sequential use of CAR T-cell based therapies in combination with monoclonal antibodies and controversy surrounding this treatment approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter